

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/699,281 10/30/2003		Paul K. Wolber	10030355-1	3574	
22878	7590 03/07/2007	EXAMINER			
AGILENT TECHNOLOGIES INC. INTELLECTUAL PROPERTY ADMINISTRATION,LEGAL DEPT.			CROW, ROBERT THOMAS		
MS BLDG. E LOVELAND.	P.O. BOX 7599 CO 80537	ART UNIT	PAPER NUMBER		
EO VEENINE,	00 00337		1634		
•			MAIL DATE	DELIVERY MODE	
			03/07/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

1	4
٠,	v

## **Advisory Action**

Application No.	Applicant(s)
10/699,281	WOLBER ET AL.
Examiner	Art Unit
Robert T. Crow	1634

Before the Filing of an Appeal Brief								
		Examiner	Art Unit					
	_	Robert T. Crow	1634					
The MAILING DATE of this com	munication appe	ars on the cover sheet with the	correspondence add	ress				
THE REPLY FILED 06 February 2007 FAILS	TO PLACE THIS	APPLICATION IN CONDITION FO	R ALLOWANCE.					
☐ The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods:								
a) The period for reply expiresmonths from the mailing date of the final rejection.  The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.  Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).								
Extensions of time may be obtained under 37 CFR nave been filed is the date for purposes of determinater 37 CFR 1.17(a) is calculated from: (1) the exset forth in (b) above, if checked. Any reply receive may reduce any earned patent term adjustment. S	ning the period of ext spiration date of the sed by the Office later see 37 CFR 1.704(b)	tension and the corresponding amount shortened statutory period for reply orig than three months after the mailing da	of the fee. The appropr pinally set in the final Offi ate of the final rejection,	riate extension fee ice action; or (2) as even if timely filed,				
<ol> <li>The Notice of Appeal was filed on filing the Notice of Appeal (37 CFR 41.3 a Notice of Appeal has been filed, any r AMENDMENTS</li> </ol>	37(a)), or any exter	nsion thereof (37 CFR 41.37(e)), to	o avoid dismissal of th	ns of the date of ne appeal. Since				
B. The proposed amendment(s) filed afte	r a final rejection	but prior to the date of filing a brief	will not be entered b	ecanse				
(a) They raise new issues that would				coause				
(b) They raise the issue of new matte	er (see NOTE belo	w);						
<ul><li>(c) They are not deemed to place the appeal; and/or</li></ul>	(c) They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for							
(d) They present additional claims wind NOTE: (See 37 CFR 1.1		· · ·	jected claims.					
4. The amendments are not in compliance			omnliant Amendment	(PTOL-324)				
5. Applicant's reply has overcome the following			omphant / monamont	(1 102 024).				
Newly proposed or amended claim(s) non-allowable claim(s).			, timely filed amendme	ent canceling the				
7. For purposes of appeal, the proposed a how the new or amended claims would The status of the claim(s) is (or will be)	be rejected is prov		ill be entered and an	explanation of				
Claim(s) allowed: None.								
Claim(s) objected to: None.								
Claim(s) rejected: 1-13 and 21-25. Claim(s) withdrawn from consideration:	14-20 and 26-28.							
AFFIDAVIT OR OTHER EVIDENCE		·						
<ol> <li>The affidavit or other evidence filed after because applicant failed to provide a sh was not earlier presented. See 37 CFF</li> </ol>	nowing of good and	it before or on the date of filing a N d sufficient reasons why the affida	lotice of Appeal will <u>n</u> vit or other evidence i	ot be entered s necessary and				
The affidavit or other evidence filed after entered because the affidavit or other e showing a good and sufficient reasons	vidence failed to c	overcome <u>all</u> rejections under appe	eal and/or appellant fa	ils to provide a				
10. 🗌 The affidavit or other evidence is ente	·	n of the status of the claims after e	entry is below or attac	hed.				
REQUEST FOR RECONSIDERATION/OTHER								
<ol> <li>The request for reconsideration has be <u>See Continuation Sheet.</u></li> </ol>			in condition for allowa	nce because:				
12. Note the attached Information Disclos 13. Other:	ure Statement(s).	•	Shuh	/				
		$\alpha$	M R. SHUKLA, PH.					
		Muscle RA SUPERVI	M Ř. SHUKLA, PH. ISORY PATENT EX	D. AMINER				

Continuation of 11. does NOT place the application in condition for allowance because: Regarding the rejection of claims 1-13 under 35 USC 103(a), Applicant argues on pages 8-10 of the Remarks that the combined teachings of McGall in view of Weng et al do not teach detection of complexes between the depurination probes and a target nucleic acid.

However, as indicated on pages 4-6 of the previous Office Action, McGall teaches detection of depurination probes by cleavage of said depurination proves after exposure to a test condition (Figure 8 and column 9, lines 39-49). The detection of McGall comprises detecting remaining label from the uncleaved oligonucleotides that are still complexed on the array (column 9, lines 50-67). Complexes of the depurinated probes are cleaved as well; thus, all of the depurination probes on the array are detected by the absence of label. The group of cleaved depurination probes includes depurination probes that were present in complexes; thus, the cleavage step detects all depurination probes, including those that were in complexes.

While McGall teaches the test conditions include operating conditions (column 11, lines 20-41) and that operating conditions include hybridization of nucleic acids to the array (column 13, lines 33-57), the specific embodiment of hybridization of a nucleic acid, which is a target, to the array followed by cleavage is not explicitly taught by McGall.

However, Weng et al teach hybridizing nucleic acids in the form of mRNA, which are targets, to a microarray as a test condition (column 4, lines 58-67 and column 8, lines 60-67). Weng et al thus clearly teach the step of hybridizing a target nucleic acid (i.e., the mRNA) to an array as a test condition. The array test condition of Weng et al is the modification applied to the test condition of McGall, which results n the added benefit of controlling the quality of the array production process as taught by Weng et al (column 5, lines 29-32).

The modification of the teachings of McGall with the target hybridization test condition of Weng et al therefore results in a method comprising all of the steps of the instant claims. The "resultant binding complexes" of the previous version of the claims were previously interpreted as binding complexes between the depurination probe and the target nucleic acid because of the limitation "resultant" that was present in the previous version of the claims. The same rejections would therefore be applied. The determination of the depurination event taught by McGall would occur as a result of detecting the binding complexes between the target nucleic acids and the depurination probes. McGall achieves this by comparing a first cleaved area of the array with a second identical uncleaved area of the array (column 9, lines 61-67). The cleavage step results in the detection of all of depurination probes, including depurination probes that were present in complexes. Thus, the cleavage step detects all depurination probes, including those that were in complexes. The complexes are detected by the absence of a signal in the treated area.

As stated in the previous Office Action, the ordinary artisan would have been motivated to make the modification because the modification would have resulted in a method of detecting depurination reaction products that has the added advantage of controlling the quality of the array production process as taught by Weng et al (column 5, lines 29-32).

Regarding the rejection of claims 21-25 under 35 USC 102(b) as anticipated by McGall, Applicant argues on pages 6-8 of the Remarks that McGall does not teach detection of the binding complexes between the depurination probe and the target nucleic acid. However, the amended claims would be rejected under 35 USC 103(a) for the reasons set forth in the rejection of claims 1-13 under 35 USC 103(a) as indicated in the previous Office Action and as outlined above.

RAM R. SHUKLA, PH.D.
SUPERVISORY PATENT EXAMINER

SUPERVISORY PATENT EXAMINER